Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.

European journal of clinical pharmacology - 1 Jun 2015

Pawlowska M, Bogiel M, Duda J, Sieradzki E

Abstract excerpt

PURPOSE: This is the first study that connects pharmacokinetics of tolperisone with genetic polymorphism of the enzymes involved in its metabolism in human. We aimed to identify the influence of polymorphism of two main enzymes (CYP2D6 and CYP2C19) on pharmacokinetic profile of parent drug. METHODS: In a single-dose study, 28 healthy Caucasian male volunteers received an oral dose of 150 mg of tolperisone. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Healthy Volunteers

Share to Heterozygote

Share to Homozygote

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 25953735
DOI: 10.1007/s00228-015-1856-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.PMID 25953735Read ↗

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.Semantic proximity Read ↗

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.Semantic proximity Read ↗

Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone.Semantic proximity Read ↗

Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.Semantic proximity Read ↗

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.Semantic proximity Read ↗

Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro.Semantic proximity Read ↗

The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.Semantic proximity Read ↗

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.Semantic proximity Read ↗

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.Semantic proximity Read ↗

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).Semantic proximity Read ↗

The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.Semantic proximity Read ↗

Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.